StockNews.com Initiates Coverage on Cellectis (NASDAQ:CLLS)

Investment analysts at StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS - Get Free Report) in a report released on Wednesday. The firm set a "sell" rating on the biotechnology company's stock.

Separately, Barclays decreased their price objective on shares of Cellectis from $7.00 to $5.00 and set an "overweight" rating for the company in a research note on Tuesday, November 5th.

Cellectis Stock Performance

Shares of CLLS remained flat at $1.98 on Wednesday. 33,706 shares of the company were exchanged, compared to its average volume of 50,188. Cellectis has a 12 month low of $1.70 and a 12 month high of $3.77. The firm has a market cap of $110.06 million, a PE ratio of -1.50 and a beta of 3.10. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48. The company has a fifty day moving average of $2.03 and a two-hundred day moving average of $2.25.

Cellectis (NASDAQ:CLLS - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.23) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.03). The company had revenue of $18.05 million during the quarter, compared to analysts' expectations of $5.00 million. Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. During the same period in the previous year, the company posted ($0.31) earnings per share. As a group, equities analysts anticipate that Cellectis will post -0.46 EPS for the current fiscal year.

Institutional Trading of Cellectis

Several hedge funds have recently added to or reduced their stakes in the stock. Long Focus Capital Management LLC raised its position in shares of Cellectis by 2.9% in the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company's stock valued at $8,634,000 after purchasing an additional 130,000 shares during the period. Principal Financial Group Inc. raised its holdings in Cellectis by 2.9% during the 2nd quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company's stock valued at $817,000 after acquiring an additional 12,467 shares during the period. First Affirmative Financial Network purchased a new stake in shares of Cellectis during the third quarter worth $45,000. Finally, XTX Topco Ltd bought a new position in shares of Cellectis in the second quarter worth $29,000. Institutional investors own 63.90% of the company's stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.